With Cash In Hand, Focus For MabVax Turns To The Clinical Program
May 22, 2017 at 13:57 PM EDT
This morning, MabVax Therapeutics closed a public offering of $4.1 million in cash. The company offered 1.343 million shares.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.